Zanidatamab for HER2-Amplified, Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Lancet Oncol 2023 Jun 02;[EPub Ahead of Print], JJ Harding, J Fan, DY Oh, HJ Choi, JW Kim, HM Chang, L Bao, HC Sun, T Macarulla, F Xie, JP Metges, J Ying, J Bridgewater, MA Lee, MA Tejani, EY Chen, DU Kim, H Wasan, M Ducreux, Y Bao, L Boyken, J Ma, P Garfin, S PantFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.